Conference Call Highlites:
1) 1Q Revenues were from the sales of securities, stocks, and other capital assets EPGL owned. Minimal sales were reported from MPDD.
2) MPDD sales (first 1,000 units and others) will be reported in 2Q. Cost of goods will be reported in this quarter as well.
3) Cost of MPDD is less than $3,000 (CEO would not go into specifics). Margin on each device should be over $10,000 a unit.
4) DTC Chill should be lifted in days, but no guarantees since it is out of the hands of EPGL. Conference call occurred today and things should happen any day now.
5) Biomems has huge profit potential. No details heard other than what we already know. They are continuing to file patents and should have over 100 when all is said and done. Dr. Markus believes the key is filing patents ahead of the competition and then focusing on the designing/redesigning the product that will ultimately be sold.
6) Company makeup consists of mainly doctors right now. EPGL is not a huge company. They have 'satellite' personnel across the US. They intend to keep production in the US as long as possible for the MPDD and other devices. The company will grow and expand (personnel numbers) with revenue growth.
7) CEO believes we are still at the starting gates and entry level for this stock. He is not happy with the 'bashers' of EPGL. Looks like he is literally referring to some members of this board. He is giving them the opportunity to talk to him directly and they have not. He is happy for those who did Q&A with him tonight and his door is open to 'bashers' who want to talk to him directly.
